Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing
Bristol Myers Squibb (BMY) is facing a patent cliff that threatens its revenue from key drugs, but the company's robust pipeline and leadership in CAR-T cell therapy may offset these losses. With a 4.3% dividend yield and upcoming 2026 catalysts, the stock may be undervalued by the current market. The article highlights BMY's strategic advantages in oncology and immunotherapy as potential drivers of future growth.
- ▪Bristol Myers Squibb is confronting a patent cliff that could impact revenue from its top-selling drugs.
- ▪The company has a strong pipeline featuring CAR-T therapies, which are poised to play a major role in cancer treatment.
- ▪Bristol Myers Squibb offers a 4.3% dividend yield, adding investor appeal despite near-term challenges.
- ▪The article identifies 2026 as a pivotal year for new product catalysts and potential valuation re-rating.
- ▪Competitors in the CAR-T and cell therapy space include Gilead Sciences, Kyverna Therapeutics, and Cabaletta Bio.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897709-bristol-myers-squibb-the-car-t-giant-the-market-is-undervaluing"},"author":{"@type":"Person","name":"Joseph…
Excerpt limited to ~120 words for fair-use compliance. The full article is at All Articles on Seeking Alpha.
Discussion
0 commentsMore from All Articles on Seeking Alpha
